Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 156,100 | 148,700 | 231,100 | 140,900 | 222,200 |
| Cost of Goods | 72,000 | 84,900 | 85,900 | 66,900 | 88,500 |
| Gross Profit | 84,100 | 63,800 | 145,200 | 74,000 | 133,700 |
| Operating Expenses | 73,600 | 92,600 | 69,600 | 73,300 | 84,300 |
| Operating Income | 10,500 | -27,900 | 76,500 | 1,600 | 49,900 |
| Interest Expense | 11,000 | 14,700 | 15,200 | 14,700 | 14,700 |
| Other Income | 13,900 | -8,100 | -3,700 | -3,700 | 57,500 |
| Pre-tax Income | 13,400 | -50,700 | 57,600 | -16,800 | 92,700 |
| Income Tax | 6,600 | 3,900 | 6,400 | -4,800 | 24,700 |
| Net Income Continuous | 6,800 | -54,600 | 51,200 | -12,000 | 68,000 |
| Net Income | $6,800 | $-54,600 | $51,200 | $-12,000 | $68,000 |
| EPS Basic Total Ops | 0.13 | -1.01 | 0.96 | -0.22 | 1.25 |
| EPS Basic Continuous Ops | 0.13 | -1.01 | 0.96 | -0.22 | 1.25 |
| EPS Diluted Total Ops | 0.07 | -0.95 | 0.91 | -0.22 | 1.19 |
| EPS Diluted Continuous Ops | 0.12 | -0.94 | 0.91 | -0.22 | 1.19 |
| EPS Diluted Before Non-Recurring Items | 0.21 | -0.43 | 1.06 | 0.16 | 0.71 |
| EBITDA(a) | $35,800 | $-1,800 | $102,400 | $27,500 | $77,600 |